AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2277475 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1,000,000 units intravenously) followed by intravenous heparin for 5-7 days
Number of subjects: 153
Study 2277475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no streptokinase treatment)
Number of subjects: 153
Study 396083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 0
Study 396083 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 30777957 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus dose of intravenous cefazolin 1 g at surgery (Group A)
Number of subjects: 338
Study 30777957 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin 500 mg postoperatively twice a day for 5 days (Group B)
Number of subjects: 338
Study 28351359 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by teaching associates who provided direct feedback on student performance
Number of subjects: 181
Study 28351359 — intervention group
Group type: COMPARATOR
Intervention: Control group: lessons by an instructor and peer‐based practical skills training
Number of subjects: 181
Study 25487172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 202
Study 25487172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 24499061 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic incisional hernia repair
Number of subjects: 270
Study 24499061 — intervention group
Group type: COMPARATOR
Intervention: Open incisional hernia repair
Number of subjects: 270
Study 21372561 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin/heparin (group A)
Number of subjects: 119
Study 21372561 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine/citrate (group B)
Number of subjects: 119
Study 21372561 — intervention group
Group type: COMPARATOR
Intervention: Heparin (group C)
Number of subjects: 119
Study 19661450 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing hypoxic gas (Fi(O2) = 0.12)
Number of subjects: 12
Study 17264338 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uracil/ftorafur (UFT) plus leucovorin (LV)
Number of subjects: 1608
Study 17264338 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorouracil (FU) plus leucovorin (LV)
Number of subjects: 1608
Study 14979748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial pattern tapping task during film viewing
Number of subjects: 0
Study 14979748 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal distraction task during film viewing
Number of subjects: 0
Study 14979748 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in state dissociation
Number of subjects: 0
Study 14979748 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in heart rate during the film
Number of subjects: 0
Study 14979748 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall and recognition measures
Number of subjects: 0
Study 11377926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release
Number of subjects: 248
Study 11377926 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 248
Study 9233710 — intervention group
Group type: EXPERIMENTAL
Intervention: pp65 antigenemia-guided early ganciclovir treatment
Number of subjects: 29
Study 9233710 — intervention group
Group type: COMPARATOR
Intervention: ganciclovir at engraftment
Number of subjects: 29
Study 9233710 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma PCR
Number of subjects: 29
Study 9233710 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL PCR
Number of subjects: 29
Study 9233710 — intervention group
Group type: EXPERIMENTAL
Intervention: pp65 antigenemia assay
Number of subjects: 29
Study 8013155 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and Lupron for 3 months
Number of subjects: 142
Study 8013155 — intervention group
Group type: COMPARATOR
Intervention: Prostatectomy alone
Number of subjects: 142
Study 3626867 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms Cr + 100 mg nicotinic acid
Number of subjects: 16
Study 3626867 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms Cr
Number of subjects: 16
Study 3626867 — intervention group
Group type: COMPARATOR
Intervention: 100 mg nicotinic acid
Number of subjects: 16
Study 2789777 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with tympanostomy tube insertion
Number of subjects: 109
Study 2789777 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy alone
Number of subjects: 109
Study 2789777 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 109
Study 30758314 — intervention group
Group type: EXPERIMENTAL
Intervention: P-RDW ratio
Number of subjects: 70
Study 28207680 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory randomized controlled trial intervention with eight family skill building sessions
Number of subjects: 352
Study 28207680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 352
Study 25189602 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Apical (RVA) pacing
Number of subjects: 240
Study 25189602 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular High Septal (RVHS) pacing
Number of subjects: 240
Study 25189602 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 240
Study 25189602 — intervention group
Group type: COMPARATOR
Intervention: RVHS pacing
Number of subjects: 240
Study 23570475 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure after incision and drainage (I&D)
Number of subjects: 56
Study 23570475 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure after incision and drainage (I&D)
Number of subjects: 56
Study 21546629 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM‐102 loading‐dose regimen (1500 mg twice per day on day 1 followed by 600 mg twice per day)
Number of subjects: 198
Study 21546629 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg twice per day)
Number of subjects: 198
Study 19558888 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion of activated-carbon particles injected into the thyroid gland of trial group patients.
Number of subjects: 36
Study 19558888 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 36
Study 19558888 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group with activated-carbon particles.
Number of subjects: 36
Study 16434580 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives ($20 for each class attended and $100 if they quit smoking 30 days post program completion)
Number of subjects: 179
Study 16434580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 179
Study 16434580 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 179
Study 14762698 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET after neoadjuvant radiochemotherapy (RCT) with combined regional hyperthermia (RHT)
Number of subjects: 22
Study 14762698 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 22
Study 11225511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 11225511 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study 11225511 — intervention group
Group type: COMPARATOR
Intervention: Therapy
Number of subjects: 0
Study 9029449 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + 2.5 mg chlorhexidine (CHX)
Number of subjects: 118
Study 9029449 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 118
Study 8333480 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 30
Study 8333480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 3552680 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg tds
Number of subjects: 12
Study 3552680 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 40 mg tds
Number of subjects: 12
Study 3552680 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 12
Study 3552680 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study 3552680 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (higher doses)
Number of subjects: 12
Study 3552680 — intervention group
Group type: EXPERIMENTAL
Intervention: Other side effects
Number of subjects: 12
Study 31646469 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated motion correction
Number of subjects: 100
Study 31646469 — intervention group
Group type: COMPARATOR
Intervention: Manual motion correction with manual review and adjustment
Number of subjects: 100
Study 31025578 — intervention group
Group type: EXPERIMENTAL
Intervention: pTURP + ADT
Number of subjects: 188
Study 31025578 — intervention group
Group type: COMPARATOR
Intervention: ADT
Number of subjects: 188
Study 28431547 — intervention group
Group type: EXPERIMENTAL
Intervention: Squire's Quest II serious game intervention
Number of subjects: 400
Study 26310363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions
Number of subjects: 81
Study 22999988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed to SRIs
Number of subjects: 67
Study 22999988 — intervention group
Group type: COMPARATOR
Intervention: Unexposed to SRIs
Number of subjects: 67
Study 21353251 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index ≥40 mL/m²
Number of subjects: 119
Study 21353251 — intervention group
Group type: COMPARATOR
Intervention: Left atrial volume index <40 mL/m²
Number of subjects: 119
Study 21353251 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative increased E/e' ratio and left ventricular hypertrophy
Number of subjects: 119
Study 21353251 — intervention group
Group type: EXPERIMENTAL
Intervention: E/e' ratio
Number of subjects: 119
Study 19039965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (target controlled infusion; 2-3 mcg x ml(‐1))
Number of subjects: 50
Study 19039965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (end‐tidal concentration 1‐2%)
Number of subjects: 50
Study 19039965 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study 19039965 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study 16520560 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexion massage (12 sessions, 30 minutes each)
Number of subjects: 50
Study 16520560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 12689610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 50 nmol of Neuropeptide Y (NPY)
Number of subjects: 14
Study 12689610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10513708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg daily on 2 consecutive days
Number of subjects: 30
Study 10513708 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (five single-volume exchanges over 2 weeks)
Number of subjects: 30
Study 10513708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution given in the same manner as IVIG)
Number of subjects: 30
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal advice and encouragement from physicians during a single routine consultation
Number of subjects: 188
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary interventions (follow-up letters or visits, demonstration of spirometry, etc.)
Number of subjects: 188
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification techniques (relaxation, rewards and punishment, avoiding 'trigger' situations, etc.)
Number of subjects: 188
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 188
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 188
Study 7575046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden cessation or gradual reduction in smoking
Number of subjects: 188
Study 1794805 — intervention group
Group type: EXPERIMENTAL
Intervention: Epikeratophakia
Number of subjects: 25
Study 1794805 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty
Number of subjects: 25
Study 6754131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 31101662 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoTapAS (mobile application for heart rate assessment)
Number of subjects: 60
Study 31101662 — intervention group
Group type: COMPARATOR
Intervention: Mental computation (control)
Number of subjects: 60
Study 29580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supply on demand distribution strategy
Number of subjects: 2000
Study 29580277 — intervention group
Group type: COMPARATOR
Intervention: Unsolicited supply distribution strategy
Number of subjects: 2000
Study 29580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both distribution methods
Number of subjects: 2000
Study 27578972 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based spirometry measurements during fluticasone propionate withdrawal over 12 weeks
Number of subjects: 0
Study 27578972 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic spirometry measurements during fluticasone propionate withdrawal over 12 weeks
Number of subjects: 0
Study 27578972 — intervention group
Group type: COMPARATOR
Intervention: Home-based spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Number of subjects: 0
Study 27578972 — intervention group
Group type: COMPARATOR
Intervention: In-clinic spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Number of subjects: 0
Study 27578972 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based spirometry measurements
Number of subjects: 0
Study 24952289 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder
Number of subjects: 502
Study 24952289 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 502
Study 22124939 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families-Teen (SAAF-T) program
Number of subjects: 502
Study 22124939 — intervention group
Group type: COMPARATOR
Intervention: Attention-control program focused on health and nutrition
Number of subjects: 502
Study 19320650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium tolerance test (OCTT) with a 10-mmol calcium dose
Number of subjects: 11
Study 19320650 — intervention group
Group type: COMPARATOR
Intervention: Dual stable isotope method
Number of subjects: 11
Study 18414202 — intervention group
Group type: EXPERIMENTAL
Intervention: PNKP T5644G variant allele
Number of subjects: 0
Study 18414202 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary components
Number of subjects: 0
Study 18414202 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16053953 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg/day
Number of subjects: 0
Study 12493339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (10 mg twice daily) plus nebulised salbutamol (2.5 mg)
Number of subjects: 13
Study 12493339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (10 mg twice daily) plus nebulised placebo
Number of subjects: 13
Study 12493339 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nebulised salbutamol (2.5 mg)
Number of subjects: 13
Study 11813717 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 30
Study 11813717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 30
Study 11813717 — intervention group
Group type: COMPARATOR
Intervention: Polycarboxylate cement
Number of subjects: 30
Study 7659146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month
Number of subjects: 48
Study 7659146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month + frequent ejaculation (at least once every three days) for one month
Number of subjects: 48
Study 7659146 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study 2576255 — intervention group
Group type: EXPERIMENTAL
Intervention: gestodene (GTD) + ethinyl estradiol (EE)
Number of subjects: 762
Study 2576255 — intervention group
Group type: COMPARATOR
Intervention: desogestrel (DSG) + ethinyl estradiol (EE)
Number of subjects: 762
Study 1270775 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene therapy three times weekly for 5 weeks
Number of subjects: 23
Study 1270775 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 1270775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 23
Study 31688909 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session intervention delivered by an occupational therapist (1 session per month)
Number of subjects: 60
Study 31307501 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-RL at 160 J/cm2
Number of subjects: 30
Study 31307501 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-RL at 320 J/cm2
Number of subjects: 30
Study 31307501 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-RL at 480 J/cm2
Number of subjects: 30
Study 31307501 — intervention group
Group type: COMPARATOR
Intervention: Temperature-matched mock irradiation (control)
Number of subjects: 30
Study 31307501 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-RL (all doses)
Number of subjects: 30
Study 29023331 — intervention group
Group type: COMPARATOR
Intervention: Plyometric training on stable surfaces (PTS)
Number of subjects: 33
Study 29023331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined plyometric training on stable and unstable surfaces (PTC)
Number of subjects: 33
Study 29023331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PTS and PTC
Number of subjects: 33
Study 24766525 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Number of subjects: 46
Study 24766525 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling
Number of subjects: 46
Study 23485539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of daclizumab (1 mg/kg) before and 14 days after transplantation
Number of subjects: 120
Study 23485539 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol only
Number of subjects: 120
Study 21644317 — intervention group
Group type: EXPERIMENTAL
Intervention: Santong tuina therapy
Number of subjects: 120
Study 21644317 — intervention group
Group type: COMPARATOR
Intervention: Conventional tuina therapy
Number of subjects: 120
Study 19250106 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0-3.5)
Number of subjects: 101
Study 19250106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 17026489 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/MET fixed-dose combination therapy (initial dose 2 mg/500 mg, uptitrated to 8 mg/2000 mg)
Number of subjects: 468
Study 17026489 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/MET fixed-dose combination therapy
Number of subjects: 468
Study 17026489 — intervention group
Group type: COMPARATOR
Intervention: MET monotherapy (initial dose 500 mg, uptitrated to 2000 mg)
Number of subjects: 468
Study 17026489 — intervention group
Group type: COMPARATOR
Intervention: RSG monotherapy (initial dose 4 mg, uptitrated to 8 mg)
Number of subjects: 468
Study 15576973 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (SERM)
Number of subjects: 0
Study 11699797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 63
Study 11699797 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 63
Study 9073134 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal nitroglycerin (5 mg/day)
Number of subjects: 19
Study 9073134 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal nitroglycerin plus spironolactone (100 mg/day)
Number of subjects: 19
Study 9073134 — intervention group
Group type: COMPARATOR
Intervention: Low-dose transdermal nitroglycerin
Number of subjects: 19
Study 9073134 — intervention group
Group type: COMPARATOR
Intervention: Low-dose transdermal nitroglycerin plus spironolactone
Number of subjects: 19
Study 7879789 — intervention group
Group type: EXPERIMENTAL
Intervention: High spouse support
Number of subjects: 254
Study 7879789 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of spouse support
Number of subjects: 254
Study 7879789 — intervention group
Group type: COMPARATOR
Intervention: End-of-class dietary goal achievement
Number of subjects: 254
Study 2646619 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-release propranolol
Number of subjects: 12
Study 2646619 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol
Number of subjects: 12
Study 2646619 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic propranolol
Number of subjects: 12
Study 2646619 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 12
Study 105386 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with a mixture of carbohydrate and essential L-amino acids
Number of subjects: 15
Study 105386 — intervention group
Group type: COMPARATOR
Intervention: Standard high-calorie non-protein diet
Number of subjects: 15
Study 31701308 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 70
Study 31701308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 µg/kg)
Number of subjects: 70
Study 30270543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) monotherapy
Number of subjects: 95
Study 27720273 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian breakfast enriched with saturated fat
Number of subjects: 80
Study 27720273 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified breakfast enriched with unsaturated fatty acids and fibers
Number of subjects: 80